Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 77,999	$ 130,101
Marketable securities, short-term	62,410	47,504
Prepaid expenses and other current assets	3,623	2,724
Total current assets	144,032	180,329
Marketable securities, long-term	43,419	15,837
Property and equipment, net	151	165
Right-of-use asset	67	105
Other assets	195	151
Total assets	187,864	196,587
Current liabilities
Accounts payable	762	1,640
Accrued clinical trial expenses	5,203	2,717
Accrued expenses and other current liabilities	2,747	3,350
Operating lease liability	67	105
Total current liabilities	8,779	7,812
Total liabilities	8,779	7,812
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized and 41,025,062 shares issued and outstanding as of March 31, 2023 and December 31, 2022	4	4
Additional paid-in capital	361,339	359,949
Accumulated deficit	(181,734)	(170,427)
Accumulated other comprehensive loss	(524)	(751)
Total stockholders’ equity	179,085	188,775
Total liabilities and stockholders’ equity	$ 187,864	$ 196,587